An Optimization Randomized Clinical Trial to Identify an Effective, Efficient Smoking Cessation Intervention in the Context of Lung Cancer Screening: Cessation and Screening to Save Lives (CASTL)

Lung Cancer

A Multi-Institutional Randomized Phase III Trial of Neoadjuvant Chemoimmunotherapy Followed By Surgery Versus Upfront Surgery in Patients With Resectable Clinical Stage II-III Non-Small Cell Lung Cancer: JCOG2317 (NATCH-ICI)

Clin Lung Cancer

Mitome N, Hamada A, Wakabayashi M, Uozumi T, Horinouchi H, Isaka M, Yotsukura M, Aokage K, Fukuda H, Watanabe SI, Tsutani Y, Lung Cancer Surgical Study Group of the Japan Clinical Oncology Group (JCOG)

doi: 10.1016/j.cllc.2026.04.006

Lung Cancer

Clinical impact of TP53 classifications in previously treated advanced driver-negative non-small cell lung cancer: A biomarker analysis of the OAK and POPLAR randomized clinical trials

Lung Cancer

Zhou DD, Lord SJ, Lin FP, Cooper WA, Zaheed M, Simes RJ, John T, Lee CK

doi: 10.1016/j.lungcan.2025.108891

Lung Cancer

A comparative analysis of heterogeneity in lung cancer screening effectiveness in two randomised controlled trials

Nat Commun

Welz M, van der Aalst CM, Alfons A, Naghi AA, Heuvelmans MA, Groen HJM, de Jong PA, Aerts J, Oudkerk M, de Koning HJ, Ten Haaf K, NELSON trial consortium

doi: 10.1038/s41467-025-63471-6

Lung Cancer

Insights from a randomized controlled trial on a digital lifestyle intervention in non-small cell lung cancer survivors following inpatient rehabilitation

Lung Cancer

Weber M, Raab AM, Schmitt KU, Büsching G, Marcin T, Riegler TF, Spielmanns M, Spielmanns S, Lauber E, Gioutsos K, Papasotiropoulos T, Wicki A, Puhan MA, Frei A

doi: 10.1016/j.lungcan.2026.109433

Lung Cancer

Lung Cancer Screening in a Population from Northeast Italy Exposed to Both Asbestos and Smoking: A Cost-Effectiveness Analysis

J Clin Med

Cosulich R, Thomas C, Barbiero F, Gillespie D, Bidoli E, Cova MA, Lovadina S, Guglielmi A, Dal Maso L, Alessandrini B, Larese Filon F, Barbone F, Baratella E

doi: 10.3390/jcm15083136

Lung Cancer

Tiragolumab Plus Atezolizumab and Chemotherapy for Advanced Nonsquamous Non-Small Cell Lung Cancer: The Phase 3 SKYSCRAPER-06 Randomized Clinical Trial

JAMA Oncol

Socinski MA, Stahel R, Lee DH, Cappuzzo F, Nishio M, Lovly CM, Ozyilkan O, Li Q, Johnson M, Garon EB, Kilickap S, Ferreira da Silva FA, Alatorre-Alexander J, Meng R, Amin R, Matheny C, Troutman S, Wen X, Patil NS, Zou W, Rodriguez-Abreu D

doi: 10.1001/jamaoncol.2026.0818

RECOMMENDED

Lung Cancer

Consensus definition of stage III non-small-cell lung cancer technical resectability to standardise inclusion criteria for clinical trials: a multisocietal EORTC-Lung Cancer Group collaboration

★ 2 Recommended by Dr. med. Martin Frey, Faculty Member

★ 2 Recommended by Dr Marcus Hesse, Faculty Member

Lancet Respir Med

Dingemans AC, Opitz I, Brunelli A, Remon J, Hendriks LEL, Edwards J, Faivre-Finn C, Reguart N, Smit EF, Levy A, Sanchez-Lorente D, Trujillo JC, Filippi AR, Stathopoulos K, Blum TG, Guckenberger M, Popat S, De Angelis R, Hofman P, von der Thüsen J, Hartemink KJ, Petersen RH, Ruffini E, Dickhoff C, Houda I, Prisciandaro E, De Ruysscher D, Derks J, Bahce I, Mariolo A, Besse B, Xenophontos E, Giaj Levra N, van Schil P, Brandão M, Berghmans T

doi: 10.1016/S2213-2600(26)00051-2

RECOMMENDED

Lung Cancer

Quality Implementation of Lung Cancer Screening System (QUILS™ 1.0): A system to support high-quality delivery of lung cancer screening in diverse settings

★ 1 Recommended by Dr. med. Martin Frey, Faculty Member

Chest

Studts JL, Knight JR, Yates AR, Alexander JL, Damron KJ, Barry AM, Studts CR, Brooks MT, Mullett TW

doi: 10.1016/j.chest.2025.10.050

COMMENTED

Lung Cancer

Effectiveness of NELSON versus PLCOm2012 lung cancer screening eligibility criteria in Germany (HANSE): a prospective cohort study

★ 3 Recommended by Dr. med. Martin Frey, Faculty Member

★ 3 Recommended and commented by Dr Marcus Hesse, Faculty Member

Lancet Oncol

Vogel-Claussen J, Bollmann BA, May K, Stiebeler S, Dettmer S, Faron A, Kuhlmann A, Schmid-Bindert G, Kaaks R, Barkhausen J, Bohnet S, Reck M, HANSE investigators

doi: 10.1016/S1470-2045(25)00490-5

Related content

A Multi-Institutional Randomized Phase III Trial of Neoadjuvant Chemoimmunotherapy Followed By Surgery Versus Upfront Surgery in Patients With Resectable Clinical Stage II-III Non-Small Cell Lung Cancer: JCOG2317 (NATCH-ICI)

Clinical impact of TP53 classifications in previously treated advanced driver-negative non-small cell lung cancer: A biomarker analysis of the OAK and POPLAR randomized clinical trials

A comparative analysis of heterogeneity in lung cancer screening effectiveness in two randomised controlled trials

Insights from a randomized controlled trial on a digital lifestyle intervention in non-small cell lung cancer survivors following inpatient rehabilitation

Lung Cancer Screening in a Population from Northeast Italy Exposed to Both Asbestos and Smoking: A Cost-Effectiveness Analysis

Tiragolumab Plus Atezolizumab and Chemotherapy for Advanced Nonsquamous Non-Small Cell Lung Cancer: The Phase 3 SKYSCRAPER-06 Randomized Clinical Trial

Consensus definition of stage III non-small-cell lung cancer technical resectability to standardise inclusion criteria for clinical trials: a multisocietal EORTC-Lung Cancer Group collaboration

Quality Implementation of Lung Cancer Screening System (QUILS™ 1.0): A system to support high-quality delivery of lung cancer screening in diverse settings

Effectiveness of NELSON versus PLCOm2012 lung cancer screening eligibility criteria in Germany (HANSE): a prospective cohort study